Carbon monoxide rapidly impairs alveolar fluid clearance by inhibiting epithelial sodium channels

Mike Althaus1, Martin Fronius, Yasmin Buchäckert

  • 1Department of Internal Medicine, University of Giessen Lung Center, Justus Liebig University, Aulweg 123 (Room 6-11), D-35392 Giessen, Germany.

Insights

Carbon monoxide (CO) inhibits sodium absorption in the lungs, impacting fluid reabsorption. This finding is crucial for understanding CO

Area of Science:

  • Pulmonary Medicine
  • Cellular Physiology
  • Toxicology

Background:

  • Carbon monoxide (CO) is explored for treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
  • Alveolar fluid reabsorption and transepithelial ion transport are vital for lung barrier function, yet their response to CO is unknown.

Purpose of the Study:

  • To investigate the effects of CO on alveolar fluid reabsorption and transepithelial ion transport in the context of ALI/ARDS.

Main Methods:

  • Isolated, ventilated, and perfused rabbit lungs were exposed to CO gas and CO-releasing molecules (CORM-3).
  • Human bronchiolar epithelial cells (H441) and rat alveolar type II cells were treated with CO donors (CORM-3, CORM-A1).
  • Amiloride-sensitive currents and sodium transport were measured using electrophysiological techniques and a nystatin permabilization approach.

Main Results:

  • CO significantly blocked (22)Na(+) clearance and alveolar fluid reabsorption in rabbit lungs.
  • CO donors irreversibly inhibited amiloride-sensitive currents in human and rat lung cells by up to 40%.
  • The inhibitory effect was localized to the apical surface, abolished by hemoglobin, and independent of cGMP and trafficking pathways.

Conclusions:

  • CO rapidly inhibits sodium absorption across the airway epithelium through a cGMP- and trafficking-independent mechanism.
  • This CO-induced inhibition may involve critical histidine residues in amiloride-sensitive channels or associated apical proteins.
  • Findings provide insights into CO's therapeutic potential and its impact on lung epithelial function in ALI/ARDS.

Related Concept Videos

Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.